Enoblituzumab, previously known as TJ-271 or MGA271, represents a innovative therapeutic specific to CD33, the surface protein found predominantly on blood cells. The agent functions as a two-pronged molecule, https://nanacgoz164254.blognody.com/49976834/enoblituzumab-a-deep-dive-into-tj-271-and-mga271